Results 151 to 160 of about 96,147 (311)

A Rare Case of Idiopathic Noncirrhotic Portal Hypertension in a Young Patient [PDF]

Ahmed Ali Aziz, Muhammad Ali Aziz, Muhammad Amir, Rehan Shah, Ijlal Akbar Ali   +4 more
openalex   +1 more source

Portal Hypertension [PDF]

Postgraduate Medical Journal, 1947
openaire   +2 more sources

Portal hypertension [PDF]

Medical Journal Armed Forces India, 2012
openaire   +2 more sources

Effect of General Anesthesia on Liver and Spleen Stiffness for Predicting High‐Risk Varices in Biliary Atresia

Hepatology Research, EarlyView.
In children with biliary atresia (BA), breath‐holding during liver and spleen stiffness (LS and SS) measurement is often difficult, raising concerns about measurement reliability in the awake state. We investigated whether performing LS and SS measurements under general anesthesia—when brief ventilation pauses are possible—could improve diagnostic ...
Shinya Yokoyama, Takashi Honda, Yoji Ishizu, Norihiro Imai, Takanori Ito, Kenta Yamamoto, Chiyoe Shirota, Takahisa Tainaka, Satoshi Makita, Masanao Nakamura, Hiroo Uchida, Hiroki Kawashima   +11 more
wiley   +1 more source

Utility of splenic transient elastography in assessing the presence of portal hypertension: A review. [PDF]

World J Methodol
Abdulrasak M, Ahmed M, Hootak S.
europepmc   +1 more source

NITRO-OXIDATIVE STRESS, VEGF AND MMP-9 IN PATIENTS WITH CIRRHOTIC AND NON-CIRRHOTIC PORTAL HYPERTENSION

, 2015
Léon Muti, Alina Elena Pârvu, Alexandra Crăciun, Nicolae Miron, Monica Acalovschi   +4 more
openalex   +2 more sources

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Interactions Between Sarcopenia, Physical Frailty and Resting Energy Expenditure in Cirrhosis and Portal Hypertension. [PDF]

Nutrients
Jacob R, Craik J, Pudipeddi A, Park L, Aw G, Ngu NLY, Sundaram P, Vidot H, Valliani T, Gill M, Staudenmann D, Bowen D, Strasser SI, McCaughan GW, Liu K.   +14 more
europepmc   +1 more source

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source

Application of propensity score matching in prognostic analysis of portal hypertension in hepatocellular carcinoma patients. [PDF]

Front Oncol
Gao Q, Zhu C, Chen M, Mo S, He Y, Huang K, Liao Y, Liang T, Han C, Peng T.   +9 more
europepmc   +1 more source